Legislative Lowdown: PBMs Must Disclose Pricing Information to Health Plans, Workers

Key Takeaways

• PBMs must report pricing data semiannually to health plans
• Full rebate pass‑through to group health plans mandated
• Net price, spread, and out‑of‑pocket costs disclosed
• Employers could see lower prescription expenses
• Federal budget office projects $2 billion savings over ten years

Pulse Analysis

Pharmacy benefit managers have long operated behind a veil of complex contracts and opaque rebate structures, allowing them to capture a portion of drug discounts without the knowledge of health plans or employers. Recent legislative momentum, driven by concerns that PBMs incentivize higher list prices to earn larger rebates, culminated in a bipartisan spending bill that codifies transparency requirements. By obligating PBMs to file detailed pricing reports—including the spread between plan payments and pharmacy reimbursements, net drug prices after all discounts, and patient out‑of‑pocket responsibilities—the law seeks to dismantle the information asymmetry that has fueled inflated drug costs.

The new mandate goes further by prohibiting PBMs from retaining any portion of manufacturer rebates, fees, or alternative discounts, compelling a 100% pass‑through to group health plans. This shift could fundamentally alter PBM business models, pushing them toward fee‑based services rather than rebate‑driven revenue. For employers, the clearer view of true drug costs enables more accurate budgeting and the ability to negotiate better formulary terms. Workers stand to benefit from reduced copays and a more transparent pricing landscape, potentially decreasing overall out‑of‑pocket spending on prescriptions.

While the reforms promise cost savings—estimated at $2 billion in federal outlays over a decade—the transition may present short‑term operational challenges. PBMs will need to overhaul reporting systems, and health plans must develop processes to analyze and act on the influx of data. Nonetheless, the legislation signals a broader regulatory trend toward accountability in the pharmaceutical supply chain, encouraging market participants to prioritize value over opaque rebate structures. Employers and policymakers will be watching closely as the 2028‑2029 rollout unfolds, assessing whether the anticipated savings materialize and how the industry adapts to a more transparent paradigm.